{"paper_id": "5ce430242bc6674c68d00110511cd1da4f53b265", "metadata": {"title": "Clinical Features of Pneumonia Caused by 2009 Infl uenza A(H1N1) Virus in Beijing, China", "authors": [{"first": "Lu", "middle": [], "last": "Bai", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Li", "middle": [], "last": "Gu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Xiao-Li", "middle": [], "last": "Zhai", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Min", "middle": [], "last": "Lu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yong", "middle": [], "last": "Lu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Li-Rong", "middle": [], "last": "Liang", "suffix": "", "affiliation": {}, "email": ""}, {"first": ";", "middle": ["Lei"], "last": "Zhang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zi-Fen", "middle": [], "last": "Gao", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Ke-Wu", "middle": [], "last": "Huang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Ying-Mei", "middle": [], "last": "Liu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Shu-Fan", "middle": [], "last": "Song", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Lin", "middle": [], "last": "Wu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yu-Dong", "middle": [], "last": "Yin", "suffix": "", "affiliation": {}, "email": ""}, {"first": ";", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Chen", "middle": [], "last": "Wang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Kimberly", "middle": [], "last": "Henricks", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Drs", "middle": [], "last": "Bai", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Gu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Cao", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Liu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Song", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yin", "middle": [")"], "last": "Wu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "(", "middle": [], "last": "Drs", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Y", "middle": [], "last": "Lu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Liang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Wang", "middle": [], "last": "Huang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Beijing", "middle": [], "last": "Chao-Yang", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Background: Data on symptoms and radiographic changes in patients with pandemic 2009 infl uenza A(H1N1 ) (A[H1N1]) pneumonia during convalescence have not been reported. Methods: During October 26, 2009, and January 23, 2010, adult patients with pneumonia with laboratory-confi rmed or clinically suspected A(H1N1)", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "Results: Of the 65 case subjects, the median age was 41 (interquartile range [IQR], 28-57) years, 60.0% were men, and 55.4% had at least one underlying medical condition. Sixty-two patients started oseltamivir therapy within a median of 5 (IQR, 4-6) days from the onset of illness, and 31 received IV corticosteroids. ARDS developed in 33 patients, and 24 were treated initially with noninvasive positive pressure ventilation (NPPV). In this group, NPPV was successful in 13 patients (54.2%). Nine patients died at a median of 16 (IQR, 10-24) days after onset of illness. Multivariate Cox regression identifi ed two independent risk factors for death: progressive dyspnea after resolution of fever (relative risk, 5.852; 95% CI, 1.395-24.541; P 5 .016) and a higher APACHE (Acute Physiology and Chronic Health Evaluation) II score on presentation (relative risk for each point, 1.312; 95% CI, 1.140-1.511; P , .001). At 3-month follow-up of survivors with A(H1N1), ground-glass opacities were still present, although diminished, in 85.7%, and diffusing capacity for carbon monoxide was mildly reduced in 61.5%.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "Abbreviations: A(H1N1) 5 pandemic 2009 infl uenza A(H1N1); APACHE 5 Acute Physiology and Chronic Health Evaluation; D lco 5 diffusing capacity for carbon monoxide; GGOs 5 ground-glass opacities; HRCT 5 high-resolution CT; IQR 5 interquartile range; LFT 5 lung function test; NPPV 5 noninvasive positive pressure ventilation; RT-PCR 5 reverse transcriptase polymerase chain reaction; SARS 5 severe acute respiratory syndrome", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "The clinical spectrum of this disease has ranged from self-limited illness to respiratory failure and death. 1 In our initial report of the A(H1N1) virus infection in China, the majority of patients had mild illness. 2, 3 Since the fi rst report of pneumonia caused by the A(H1N1) virus in Mexico, 4 severe cases have been documented throughout the world. As of March 7, 2010, \u0546 16,713 laboratoryconfi rmed cases of death have been reported by the six world regions. 5 In mainland China, there were . 127,000 confi rmed cases up to February 28, 2010, including 793 deaths. 6 Many studies have been published on the clinical manifestations of A(H1N1) pneumonia during the acute phase of illness, [7] [8] [9] [10] [11] [12] [13] [14] [15] but no information has been reported on symptoms and radiographic and lung function changes in convalescence. We studied clinical manifestations during the acute phase, antiviral and corticosteroid therapy, noninvasive positive pressure ventilation (NPPV), and the histopathologic changes of a fatal case. Survivors were followed up after discharge for a period of 3 months. We believe Patient follow-up and further investigation at follow-up were carried out according to clinical need, so written informed consent was not sought. High-resolution CT (HRCT) scanning was ordered only in those with persisting symptoms, chest signs, or radiologic fi ndings on discharge or on last visit. No contrast was given with CT scan, and the possible radiation harm was also explained to patients. Lung function tests (LFTs) were ordered in those patients still attending at 3 months. The ethics board committee at Beijing Chao-Yang Hospital approved the study design.", "cite_spans": [{"start": 217, "end": 219, "text": "2,", "ref_id": "BIBREF1"}, {"start": 695, "end": 698, "text": "[7]", "ref_id": "BIBREF17"}, {"start": 699, "end": 702, "text": "[8]", "ref_id": "BIBREF18"}, {"start": 703, "end": 706, "text": "[9]", "ref_id": "BIBREF19"}, {"start": 707, "end": 711, "text": "[10]", "ref_id": "BIBREF20"}, {"start": 712, "end": 716, "text": "[11]", "ref_id": "BIBREF21"}, {"start": 717, "end": 721, "text": "[12]", "ref_id": "BIBREF22"}, {"start": 722, "end": 726, "text": "[13]", "ref_id": "BIBREF23"}, {"start": 727, "end": 731, "text": "[14]", "ref_id": "BIBREF24"}, {"start": 732, "end": 736, "text": "[15]", "ref_id": "BIBREF5"}], "ref_spans": [], "section": ""}, {"text": "The severity of lung changes was evaluated initially and on follow-up examinations. Each lung was divided into three zones. 16 The number of abnormal zones and the changes in ground-glass opacities (GGOs), consolidation, reticular-nodules, and interlobular septal thickening were evaluated by HRCT scanning. All evaluations were performed by two radiologists who were blinded to the clinical information.", "cite_spans": [], "ref_spans": [], "section": "Radiologic Evaluation"}, {"text": "LFTs, including lung volume, spirometry, and diffusing capacity for carbon monoxide (D lco ) were performed 3 months after the onset of symptoms. All LFTs were performed in accordance with recommended standards. D lco was measured with a singlebreath technique, adjusted for hemoglobin and alveolar volume. LFT measurements were considered abnormal if they were , 80% of the predicted value.", "cite_spans": [], "ref_spans": [], "section": "Lung Function Testing"}, {"text": "Continuous variables were summarized as means ( 6 SD) or medians (interquartile range [IQR] ). Differences between groups were assessed using the x 2 test or Fisher exact test for categorical variables and the Mann-Whitney U test for continuous variables. We used univariate and multivariate Cox regression to identify independent predictors of mortality. All analyses were performed by SPSS software,version 13.0 (SPSS Inc; Chicago, Illinois). A P value \u0545 .05 was considered statistically signifi cant.", "cite_spans": [{"start": 86, "end": 91, "text": "[IQR]", "ref_id": null}], "ref_spans": [], "section": "Statistical Analysis"}, {"text": "From October 26, 2009, to January 23, 2010, a total of 2,415 cases of infl uenza-like illness were reported in our hospital, of which 516 were laboratory-confi rmed A(H1N1) cases. During the epidemic, a total of 65 patients were eligible for this study, including 62 patients with laboratory-confi rmed A(H1N1) and three patients with high clinical suspicion for A(H1N1) infection. Among the 65 patients, 50 were hospitalized, and 15 were treated as outpatients.", "cite_spans": [], "ref_spans": [], "section": "Results"}, {"text": "Median age was 41 years, 60.0% were men, and 55.4% had at least one underlying medical condition ( Table 1 ) . Dyspnea persisted in 13.8% of patients after resolution of fever. Smokers were more common in the ARDS group ( P 5 .067), and moist rales and wheezing were signifi cantly more frequent in this group. Although leukocyte counts were similar in the two our work can help optimize treatment, and also lead to a better understanding of the symptomatic, radiologic, and lung functional changes during the convalescent period.", "cite_spans": [], "ref_spans": [{"start": 97, "end": 108, "text": "( Table 1 )", "ref_id": "TABREF0"}], "section": "Clinical Characteristics"}, {"text": "Data were collected retrospectively and prospectively on all patients with confi rmed A(H1N1)-related pneumonia treated at Beijing Chao-Yang Hospital between October 26, 2009, and January 23, 2010. The diagnosis of pneumonia was based on respiratory symptoms combined with a new infi ltrate on chest radiograph. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay was used to confi rm the diagnosis of A(H1N1) infection. Patients presenting with pneumonia with high clinical suspicion of A(H1N1) infection but negative RT-PCR test results for A(H1N1) were also included in this study. Children younger than 14 years of age were excluded. Most patients were hospitalized for treatment, whereas those who presented with less serious illness and did not need oxygen supplementation were treated as outpatients under home quarantine.", "cite_spans": [], "ref_spans": [], "section": "Study Patients and Case Defi nition"}, {"text": "Treatment decisions for all patients were made by their attending physicians. Hospitalized patients were discharged when their temperatures had returned to normal for at least 3 days, most infl uenza-like symptoms had disappeared, and they were clinically stable.", "cite_spans": [], "ref_spans": [], "section": "Study Patients and Case Defi nition"}, {"text": "Information recorded included demographic data, underlying medical conditions, symptoms, signs, laboratory and chest radiograph fi ndings before therapy and during follow-up, and the clinical course, treatment, and adverse events during hospital stay. APACHE (Acute Physiology and Chronic Health Evaluation) II scores were determined in all patients to assess the severity of illness. During hospitalization, clinical data were collected retrospectively from medical records. zones on chest radiograph ( P 5 .002) than did those who were outpatients.", "cite_spans": [], "ref_spans": [], "section": "Data Collection During Hospitalization and Follow-up"}, {"text": "Sixty-two of 65 patients started oseltamivir therapy within a median of 5 (IQR, 4-6) days from the onset of illness. Dosages and duration of antiviral therapy are listed in Table 1 . Thirty-one patients received IV corticosteroids for a median duration of 3 (IQR, 3-6) days, with a dose of methylprednisolone, 1-3 mg/kg/d.", "cite_spans": [], "ref_spans": [{"start": 173, "end": 180, "text": "Table 1", "ref_id": "TABREF0"}], "section": "Medication Treatment"}, {"text": "Adverse effects involving hallucinations and disorientation occurred in three male hospitalized patients 24 to 36 h after beginning corticosteroids or oseltamivir. Two of the three patients received both drugs, and the other one received only oseltamivir. Symptoms groups, lymphocyte counts were signifi cantly lower and serum potassium levels signifi cantly higher in the ARDS group. Patients with ARDS also required more frequent use of higher doses of oseltamivir, longer duration of oseltamivir treatment, and more frequent use of corticosteroids and vasopressors, and more frequently had positive bacterial and fungal cultures. The most common initial radiologic fi ndings on HRCT scan were bilateral GGOs involving several zones with or without associated multifocal areas of consolidation. Centrilobular nodules were also common, and small pleural effusions were present in 25.7% of patients ( Fig 1 ) . In patients without ARDS, those who were hospitalized more frequently had diarrhea ( P 5 .003), moist rales ( P 5 .001), a lower serum albumin level ( P 5 .011), and more involved lung ; without ARDS group (n 5 25); with ARDS group (n 5 33). g Chest radiograph was performed within 1 wk after onset of symptoms. Total (N 5 57); without ARDS group (n 5 29); with ARDS group (n 5 28). h High-resolution chest CT scanning was performed at a median 6 (interquartile range, 4-9) days after onset of symptoms. Total (N 5 35); without ARDS group (n 5 14); with ARDS group (n 5 21). disappeared 1 to 2 days after stopping corticosteroids and oseltamivir or lowering the dose of oseltamivir.", "cite_spans": [], "ref_spans": [{"start": 899, "end": 908, "text": "( Fig 1 )", "ref_id": "FIGREF3"}], "section": "Medication Treatment"}, {"text": "Among 33 patients with ARDS, 24 required ventilation support, all of whom were initially treated with NPPV. In this group, NPPV succeeded in 13 (54.2%) (duration 5.1 6 2.8 days) and 10 (41.7%) failed and were intubated at a median of 16 (IQR, 10-84) h after admission; the last one refused intubation and died. Among the 10 patients who were intubated, eight died. Patients who failed NPPV treatment had higher APACHE II scores on presentation (median 13 [IQR, [11] [12] [13] [14] ) compared with those who succeeded Table 4 ) , who was treated successfully with oseltamivir and noninvasive positive pressure ventilation. A, Initial high-resolution CT (HRCT) scan obtained 12 days after onset of illness shows bilateral extensive ground-glass opacities (GGOs) and multifocal consolidation that had a predominant subpleural distribution. B, HRCT scan obtained 29 days after onset of illness shows GGOs, interlobular septal thickening, and reticular nodules pattern (arrows). C, On day 54, only GGOs are seen. D, At a 3-month visit, GGOs are still present but are much improved. E and F, The same scan as A shows centrilobular nodules in the left upper lobe (arrows in E) and a very small amount of right pleural effusion (arrow in F).", "cite_spans": [{"start": 461, "end": 465, "text": "[11]", "ref_id": "BIBREF21"}, {"start": 466, "end": 470, "text": "[12]", "ref_id": "BIBREF22"}, {"start": 471, "end": 475, "text": "[13]", "ref_id": "BIBREF23"}, {"start": 476, "end": 480, "text": "[14]", "ref_id": "BIBREF24"}], "ref_spans": [{"start": 517, "end": 524, "text": "Table 4", "ref_id": "TABREF4"}], "section": "Ventilation Support"}, {"text": "(median 10 [IQR, [9] [10] [11] ; P 5 .020). Barotrauma occurred in two patients, one during extracorporeal membrane oxygenation therapy.", "cite_spans": [{"start": 17, "end": 20, "text": "[9]", "ref_id": "BIBREF19"}, {"start": 21, "end": 25, "text": "[10]", "ref_id": "BIBREF20"}, {"start": 26, "end": 30, "text": "[11]", "ref_id": "BIBREF21"}], "ref_spans": [], "section": "Ventilation Support"}, {"text": "Sputum or transtracheal aspirate specimens obtained for bacterial culture were positive in 13 patients ( Table 1 ) , including Acinetobacter baumannii, four; Klebsiella pneumoniae, four; Pseudomonas aeruginosa, two; Enterobacter aerogenes , one; Escherichia coli, one; Staphylococcus aureus, one; and A spergillus spp, six . Only one patient had a positive sputum culture within the fi rst 48 h of hospitalization ( Klebsiella pneumoniae ). All other positive bacterial or fungal cultures were obtained \u0546 48 h after hospitalization.", "cite_spans": [], "ref_spans": [{"start": 103, "end": 114, "text": "( Table 1 )", "ref_id": "TABREF0"}], "section": "Coinfections"}, {"text": "An autopsy was performed on a 44-year-old previously healthy man who was admitted 7 days after onset of symptoms and died of severe ARDS on day 18 of hospitalization ( Fig 2 ) . Gross examination of lung tissue revealed prominent congestion and consolidation, with increased weight (left, 860 g; right, 1,178 g). An abscess was seen in the right lower lobe that ", "cite_spans": [], "ref_spans": [{"start": 166, "end": 175, "text": "( Fig 2 )", "ref_id": "FIGREF2"}], "section": "Postmortem Findings"}, {"text": "Among the 65 patients, nine died, of whom eight had hemorrhagic respiratory secretions. One 19-yearold man died of severe hemoptysis within 24 h of admission. The death rate among patients with ARDS was 27.3% (9/33). The main cause of death was refractory hypoxemia. Two factors were found to be independently associated with death: progressive dyspnea after resolution of fever (relative risk, 5.852; 95% CI, 1.395-24.541; P 5 .016) and a higher APACHE II score on presentation (relative risk for each point, 1.312; 95% CI, 1.140-1.511; P , .001) ( Table 2 ) .", "cite_spans": [], "ref_spans": [{"start": 550, "end": 559, "text": "Table 2 )", "ref_id": "TABREF3"}], "section": "Outcome and Predictors of Mortality"}, {"text": "Of the 56 survivors, 39 had one or more follow-up visits. Among 14 who completed the 3-month visits, symptoms reported at the last visit included exertional dyspnea (four), hair loss (two), and cough (one). The duration of symptoms was as follows: sputum 19.6 6 6.6 days, bloody sputum 11.0 6 4.1 days, fatigue 16.0 6 7.7 days. A 31-year-old female patient who was previously healthy still had a low platelet count of 34,000 per mm 3 at 75 days after the onset of illness.", "cite_spans": [], "ref_spans": [], "section": "Follow-up in Survivors"}, {"text": "Changes in lung abnormalities from initial to follow-up HRCT scan examinations are shown in Table 3 . Among the 14 patients who completed their 3-month visit, 12 still showed lesser degrees of GGOs ( Fig 1 ) . In those who had ARDS (n 5 9), \"involved zones\" were signifi cantly ( P 5 .002) more frequent than in those without ARDS (n 5 5).", "cite_spans": [], "ref_spans": [{"start": 92, "end": 99, "text": "Table 3", "ref_id": "TABREF2"}, {"start": 198, "end": 207, "text": "( Fig 1 )", "ref_id": "FIGREF3"}], "section": "Follow-up in Survivors"}, {"text": "LFTs were performed at visit 3 for 13 patients ( Table 4 ). All 13 had been hospitalized, and there was no statistical difference in clinical and laboratory characteristics between these patients and those in whom LFTs were not obtained. Impairment of D lco was the most common (8/13 [61.5%]) abnormality detected. Data are presented as median (interquartile range) unless otherwise indicated. A(H1N1) 5 2009 infl uenza A(H1N1). See Table 1 ", "cite_spans": [], "ref_spans": [{"start": 47, "end": 56, "text": "( Table 4", "ref_id": "TABREF4"}, {"start": 433, "end": 440, "text": "Table 1", "ref_id": "TABREF0"}], "section": "Follow-up in Survivors"}, {"text": "Our series of 65 cases of A(H1N1) identifi ed two independent risk factors associated with fatal pneumonia: progressive dyspnea after resolution of fever and a higher APACHE II score on presentation. Three months later, GGOs of less severity were still present on chest radiographs in 85.7% of patients (12/14) . LFTs revealed decreased D lco ( , 80% predicted) in eight (61.5%) of the 13 patients tested.", "cite_spans": [{"start": 303, "end": 310, "text": "(12/14)", "ref_id": null}], "ref_spans": [], "section": "Discussion"}, {"text": "The clinical characteristics of A(H1N1) pneumonia we described during the acute phase were similar to those reported by others. [8] [9] [10] [11] [12] [13] [14] [15] In this report, most patients complained of dyspnea, which usually occurred within 1 week after illness onset. Dyspnea continued to progress after resolution of fever in 13.8% of the patients, a fi nding that has not been reported by others.", "cite_spans": [{"start": 128, "end": 131, "text": "[8]", "ref_id": "BIBREF18"}, {"start": 132, "end": 135, "text": "[9]", "ref_id": "BIBREF19"}, {"start": 136, "end": 140, "text": "[10]", "ref_id": "BIBREF20"}, {"start": 141, "end": 145, "text": "[11]", "ref_id": "BIBREF21"}, {"start": 146, "end": 150, "text": "[12]", "ref_id": "BIBREF22"}, {"start": 151, "end": 155, "text": "[13]", "ref_id": "BIBREF23"}, {"start": 156, "end": 160, "text": "[14]", "ref_id": "BIBREF24"}, {"start": 161, "end": 165, "text": "[15]", "ref_id": "BIBREF5"}], "ref_spans": [], "section": "Discussion"}, {"text": "In this report, the success rate for NPPV was 54.2%, which is much higher than that reported by others (14.5%-27.3%). 7, [12] [13] [14] Although the death rate (8/10 [80%]) in patients who received invasive ventilation in our study was higher than that reported in another study, 7 among patients with ARDS, the death rate was 27.3%, similar to other reports. 7, 8, [11] [12] [13] [14] [15] Moreover, although NPPV was used widely in the ward specifi cally set aside for patients infected with A(H1N1), none of the 28 doctors and nurses who were in direct contact with these patients developed respiratory symptoms or infl uenza-like illnesses. Therefore, we believe that with proper infection-control procedures, NPPV can be used successfully and safely for treating patients with A(H1N1) pneumonia complicated by ARDS.", "cite_spans": [{"start": 118, "end": 120, "text": "7,", "ref_id": "BIBREF17"}, {"start": 121, "end": 125, "text": "[12]", "ref_id": "BIBREF22"}, {"start": 126, "end": 130, "text": "[13]", "ref_id": "BIBREF23"}, {"start": 131, "end": 135, "text": "[14]", "ref_id": "BIBREF24"}, {"start": 360, "end": 362, "text": "7,", "ref_id": "BIBREF17"}, {"start": 363, "end": 365, "text": "8,", "ref_id": "BIBREF18"}, {"start": 366, "end": 370, "text": "[11]", "ref_id": "BIBREF21"}, {"start": 371, "end": 375, "text": "[12]", "ref_id": "BIBREF22"}, {"start": 376, "end": 380, "text": "[13]", "ref_id": "BIBREF23"}, {"start": 381, "end": 385, "text": "[14]", "ref_id": "BIBREF24"}, {"start": 386, "end": 390, "text": "[15]", "ref_id": "BIBREF5"}], "ref_spans": [], "section": "Discussion"}, {"text": "It has been reported that 29% to 55% of autopsied patients with A(H1N1) had evidence of bacterial coinfection. 17, 18 Streptococcus pneumoniae, Streptococcus pyogenes , and S aureus were the most predominant pathogens. However, in our study, community-acquired bacterial infection (defi ned as sputum collected within 48 h of hospitalization) was detected in only one of 50 patients ( K pneumoniae ). The low yield of gram-positive bacteria before or within 48 h of hospitalization may be due to the widespread use of prophylactic antibiotic therapy. In contrast, nosocomial infection was common in the patients (12/50 [24.0%]), and gram-negative bacilli were the predominant causative pathogens. Aspergillus spp was also seen. Progressive A(H1N1) infection, intubation, a prolonged hospital stay, IV antibiotic use, and use of oral or IV corticosteroids may be risk factors for nosocomial infection caused by gram-negative bacilli and Aspergillus spp.", "cite_spans": [{"start": 111, "end": 114, "text": "17,", "ref_id": "BIBREF7"}], "ref_spans": [], "section": "Discussion"}, {"text": "We showed that symptoms and laboratory abnormalities in survivors of A(H1N1) virus infection returned to normal within 1 month of the onset of illness. Nonetheless, GGOs were still found at 3 months, although no fi brotic changes were seen. In survivors of A(H5N1) virus infection, persistent radiologic abnormalities including GGOs, often with a reticular pattern, have been seen as long as 1 year after illness onset. 19 In survivors of severe acute respiratory syndrome (SARS) followed for 1 year, marked improvements in pulmonary fi brosis have been seen, but some patients still had residual changes. 20 Because this kind of fi brosis was reversible, it has been suggested that these fi ndings were partially caused by postinflammatory atelectasis rather than by genuine fi brosis alone. 21 The resolution of lung abnormalities in patients with A(H1N1) viral pneumonia seemed better than that seen in patients with SARS and infl uenza A(H5N1) infection. Impairment of D lco was the most common (8/13 [61.5%]) abnormality in lung function testing 3 months after the onset of illness, followed by restrictive defects (2/13 [15.4%] ). The D lco fi ndings were similar to the fi ndings of one study of patients with SARS at 3-month follow-up visits. 22 The impairment of D lco in survivors of SARS persisted for 1 year in 23.7% of patients reported by other investigators. 23 Although the number of cases with LFTs in our series is limited (only 13 cases, of whom eight had a reduction of D lco ), it seemed that patients who had bilateral GGOs on HRCT scan were more likely to have an impaired D lco . During the convalescent period of ARDS, GGOs may consist of intralobular fi brosis that is below the limits of resolution of HRCT scanning. 24 A longer follow-up study is needed to determine whether lung function abnormalities in patients infected with A(H1N1) are irreversible and radiologic changes persist over time.", "cite_spans": [{"start": 1126, "end": 1133, "text": "[15.4%]", "ref_id": null}], "ref_spans": [], "section": "Discussion"}, {"text": "To our knowledge, this is the fi rst report of symptoms and radiographic changes in patients with A(H1N1) pneumonia during the convalescent period. There were several limitations. First, it is a singlecenter study with a limited number of patients. Second, monthly follow-up visits were offered to all patients when they were discharged but some of the patients felt that was inconvenient and did not come back. As a result, 39 out of 56 survivors had one or more follow-up visits. Third, most patients had underlying medical conditions that could have contributed to the lung function abnormalities.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "In conclusion, we found that progressive dyspnea after resolution of fever and a higher APACHE II score on presentation were independent risk factors associated with death in patients with A(H1N1) viral pneumonia. At the 3-month follow-up visit of survivors of A(H1N1) pneumonia, some degree of GGOs persisted in most patients and decreased D lco was common.", "cite_spans": [], "ref_spans": [], "section": "Conclusions"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Clinical management of human infection with pandemic (H1N1) 2009 : revised guidance. World Health Organization Web site", "authors": [], "year": 2009, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "National Infl uenza A Pandemic (H1N1) 2009 Clinical Investigation Group . Clinical and epidemiologic characteristics of 3 early cases of infl uenza A pandemic (H1N1) 2009 virus infection, People's Republic of China", "authors": [{"first": "C", "middle": [], "last": "Bin", "suffix": ""}, {"first": "L", "middle": [], "last": "Xingwang", "suffix": ""}, {"first": "S", "middle": [], "last": "Yuelong", "suffix": ""}], "year": 2009, "venue": "Emerg Infect Dis", "volume": "15", "issn": "9", "pages": "1418--1422", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "National Infl uenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China . Clinical features of the initial cases of 2009 pandemic infl uenza A (H1N1) virus infection in China", "authors": [{"first": "B", "middle": [], "last": "Cao", "suffix": ""}, {"first": "X", "middle": ["W"], "last": "Li", "suffix": ""}, {"first": "Y", "middle": [], "last": "Mao", "suffix": ""}], "year": 2009, "venue": "N Engl J Med", "volume": "361", "issn": "26", "pages": "2507--2517", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "INER Working Group on Infl uenza . Pneumonia and respiratory failure from swine-origin infl uenza A (H1N1) in Mexico", "authors": [{"first": "R", "middle": [], "last": "Perez-Padilla", "suffix": ""}, {"first": "D", "middle": [], "last": "De La Rosa-Zamboni", "suffix": ""}, {"first": "Ponce", "middle": [], "last": "De Leon", "suffix": ""}, {"first": "S", "middle": [], "last": "", "suffix": ""}], "year": 2009, "venue": "N Engl J Med", "volume": "361", "issn": "7", "pages": "680--689", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Utah due to novel 2009 influenza A(H1N1) infection", "authors": [], "year": 2010, "venue": "Chest", "volume": "137", "issn": "4", "pages": "752--758", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "ANZIC Influenza Investigators . Critical care services and 2009 H1N1 infl uenza in Australia and New Zealand", "authors": [{"first": "S", "middle": ["A"], "last": "Webb", "suffix": ""}, {"first": "V", "middle": [], "last": "Pettil\u00e4", "suffix": ""}, {"first": "I", "middle": [], "last": "Seppelt", "suffix": ""}], "year": 2009, "venue": "N Engl J Med", "volume": "361", "issn": "20", "pages": "1925--1934", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Severe acute respiratory syndrome: temporal lung changes at thin-section CT in 30 patients", "authors": [{"first": "G", "middle": ["C"], "last": "Ooi", "suffix": ""}, {"first": "P", "middle": ["L"], "last": "Khong", "suffix": ""}, {"first": "N", "middle": ["L"], "last": "M\u00fcller", "suffix": ""}], "year": 2004, "venue": "Radiology", "volume": "230", "issn": "3", "pages": "836--844", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic infl uenza A (H1N1)-United States", "authors": [], "year": 2009, "venue": "Centers for Disease Control and Prevention (CDC)", "volume": "58", "issn": "", "pages": "1071--1074", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Pulmonary pathologic fi ndings of fatal 2009 pandemic infl uenza A/H1N1 viral infections", "authors": [{"first": "J", "middle": ["R"], "last": "Gill", "suffix": ""}, {"first": "Z", "middle": ["M"], "last": "Sheng", "suffix": ""}, {"first": "S", "middle": ["F"], "last": "Ely", "suffix": ""}], "year": 2010, "venue": "Arch Pathol Lab Med", "volume": "134", "issn": "2", "pages": "235--243", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Radiological features of lung changes caused by avian infl uenza subtype A H5N1 virus: report of two severe adult cases with regular follow-up", "authors": [{"first": "P", "middle": ["X"], "last": "Lu", "suffix": ""}, {"first": "Y", "middle": ["X"], "last": "Wang", "suffix": ""}, {"first": "B", "middle": ["P"], "last": "Zhou", "suffix": ""}], "year": 2010, "venue": "Chin Med J (Engl)", "volume": "123", "issn": "1", "pages": "100--104", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Dynamic changes of serum SARScoronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge", "authors": [{"first": "L", "middle": [], "last": "Xie", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "B", "middle": [], "last": "Fan", "suffix": ""}], "year": 2005, "venue": "Respir Res", "volume": "6", "issn": "", "pages": "", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period", "authors": [{"first": "K", "middle": ["T"], "last": "Wong", "suffix": ""}, {"first": "G", "middle": ["E"], "last": "Antonio", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Hui", "suffix": ""}], "year": 2004, "venue": "J Comput Assist Tomogr", "volume": "28", "issn": "6", "pages": "790--795", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome", "authors": [{"first": "K", "middle": ["C"], "last": "Ong", "suffix": ""}, {"first": "A", "middle": ["W"], "last": "Ng", "suffix": ""}, {"first": "L", "middle": ["S"], "last": "Lee", "suffix": ""}], "year": 2004, "venue": "Eur Respir J", "volume": "24", "issn": "3", "pages": "436--442", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors", "authors": [{"first": "D", "middle": ["S"], "last": "Hui", "suffix": ""}, {"first": "K", "middle": ["T"], "last": "Wong", "suffix": ""}, {"first": "F", "middle": ["W"], "last": "Ko", "suffix": ""}], "year": 2005, "venue": "Chest", "volume": "128", "issn": "4", "pages": "2247--2261", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Acute respiratory distress syndrome: imaging of the injured lung", "authors": [{"first": "S", "middle": ["R"], "last": "Desai", "suffix": ""}], "year": 2002, "venue": "Clin Radiol", "volume": "57", "issn": "1", "pages": "8--17", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "Pandemic (H1N1) 2009 . World Health Organization Web site", "authors": [], "year": 2010, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Ministry of Health of the People's Republic of China . Pandemic H1N1 in China. Ministry of Health Web site", "authors": [], "year": 2010, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "H1N1 SEMICYUC Working Group . Intensive care adult patients with severe respiratory failure caused by Infl uenza A (H1N1)v in Spain", "authors": [{"first": "J", "middle": [], "last": "Rello", "suffix": ""}, {"first": "A", "middle": [], "last": "Rodr\u00edguez", "suffix": ""}, {"first": "P", "middle": [], "last": "Iba\u00f1ez", "suffix": ""}], "year": 2009, "venue": "Crit Care", "volume": "13", "issn": "5", "pages": "", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team . Hospitalized patients with 2009 H1N1 infl uenza in the United States", "authors": [{"first": "S", "middle": [], "last": "Jain", "suffix": ""}, {"first": "L", "middle": [], "last": "Kamimoto", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Bramley", "suffix": ""}], "year": 2009, "venue": "N Engl J Med", "volume": "361", "issn": "20", "pages": "1935--1944", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "Hospitalised adult patients with pandemic (H1N1) 2009 infl uenza in Melbourne, Australia", "authors": [{"first": "J", "middle": ["T"], "last": "Denholm", "suffix": ""}, {"first": "C", "middle": ["L"], "last": "Gordon", "suffix": ""}, {"first": "P", "middle": ["D"], "last": "Johnson", "suffix": ""}], "year": 2010, "venue": "Med J Aust", "volume": "192", "issn": "2", "pages": "84--86", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "California Pandemic (H1N1) Working Group . Factors associated with death or hospitalization due to pandemic 2009 infl uenza A(H1N1) infection in California", "authors": [{"first": "J", "middle": ["K"], "last": "Louie", "suffix": ""}, {"first": "M", "middle": [], "last": "Acosta", "suffix": ""}, {"first": "K", "middle": [], "last": "Winter", "suffix": ""}], "year": 2009, "venue": "JAMA", "volume": "302", "issn": "17", "pages": "1896--1902", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 infl uenza in Taiwan", "authors": [{"first": "Y", "middle": ["S"], "last": "Chien", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Su", "suffix": ""}, {"first": "H", "middle": ["T"], "last": "Tsai", "suffix": ""}], "year": 2010, "venue": "J Infect", "volume": "60", "issn": "2", "pages": "168--174", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Canadian Critical Care Trials Group H1N1 Collaborative . Critically ill patients with 2009 infl uenza A(H1N1) infection in Canada", "authors": [{"first": "A", "middle": [], "last": "Kumar", "suffix": ""}, {"first": "R", "middle": [], "last": "Zarychanski", "suffix": ""}, {"first": "R", "middle": [], "last": "Pinto", "suffix": ""}], "year": 2009, "venue": "JAMA", "volume": "302", "issn": "17", "pages": "1872--1879", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "Critically ill patients with 2009 infl uenza A(H1N1) in Mexico", "authors": [{"first": "G", "middle": [], "last": "Dom\u00ednguez-Cherit", "suffix": ""}, {"first": "S", "middle": ["E"], "last": "Lapinsky", "suffix": ""}, {"first": "A", "middle": ["E"], "last": "Macias", "suffix": ""}], "year": 2009, "venue": "JAMA", "volume": "302", "issn": "17", "pages": "1880--1887", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "Clinical fi ndings and demographic factors associated with ICU admission", "authors": [{"first": "", "middle": [], "last": "Miller Rr 3rd", "suffix": ""}, {"first": "B", "middle": ["A"], "last": "Markewitz", "suffix": ""}, {"first": "R", "middle": ["T"], "last": "Rolfs", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "utbreaks of novel 2009 influenza A(H1N1) (A[H1N1]) virus infection occurred in April 2009 in the United States and Mexico.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "Continued)", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Histopathologic changes of lung tissue sample of one fatal case. A, Gross fi ndings of right lung. B-E, Microscopic fi ndings of the specimen (hematoxylin and eosin, original magnifi cation 3 100 [B, D] or original magnifi cation 3 400 [C, E]) show diffuse alveolar damage, formation of hyaline membrane, thickening of alveolar septa, and infl ammatory cell infi ltration with fi brinous exudates. F, The right lower lobe abscess shows Aspergillus spp hyphae microscopically (hematoxylin and eosin, original magnifi cation 3 100).", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Radiologic fi ndings during follow-up of a 49-year-old male discharged patient with 2009 infl uenza A(H1N1) (A[H1N1]) (patient No. 5 in", "latex": null, "type": "figure"}, "FIGREF4": {"text": "for expansion of the other abbreviation. a Total (N 5 59); survived group (n 5 50); died group (n 5 9). b Total (N 5 58); survived group (n 5 49); died group (n 5 9).", "latex": null, "type": "figure"}, "TABREF0": {"text": "Characteristics", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>\u00a0</td><td>Patients\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Variable\n</td><td>Total (N 5 65) a </td><td>Without ARDS (n 5 32)a </td><td>With ARDS (n 5 33)a </td><td> P Value</td></tr><tr><td>Characteristic </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Male sex </td><td>39 (60.0) </td><td>19 (59.4) </td><td>20 (60.6) </td><td>.919\n</td></tr><tr><td>Age, y </td><td>41 (28-57) </td><td>36 (28-53) </td><td>46 (34-60) </td><td>.069\n</td></tr><tr><td>Range </td><td>14-75 </td><td>18-67 </td><td>14-75 </td><td>\u2026\n</td></tr><tr><td>BMI  30 kg/m 2 </td><td>15 (23.1) </td><td>6 (18.8) </td><td>9 (27.3) </td><td>.415\n</td></tr><tr><td>Underlying medical condition </td><td>36 (55.4) </td><td>13 (40.6) </td><td>23 (69.7) </td><td>.018\n</td></tr><tr><td>Asthma </td><td>3 (4.6) </td><td>2 (6.3) </td><td>1 (3.0) </td><td>.613\n</td></tr><tr><td>COPD </td><td>2 (3.1) </td><td>1 (3.1) </td><td>1 (3.0) </td><td>1.000\n</td></tr><tr><td>Chronic bronchitis </td><td>3 (4.6) </td><td>1 (3.1) </td><td>2 (6.1) </td><td>1.000\n</td></tr><tr><td>Bronchiectasis </td><td>2 (3.1) </td><td>1 (3.1) </td><td>1 (3.0) </td><td>1.000\n</td></tr><tr><td>Obstructive sleep apnea syndrome </td><td>4 (6.2) </td><td>1 (3.1) </td><td>3 (9.1) </td><td>.613\n</td></tr><tr><td>Hypertension </td><td>17 (26.2) </td><td>5 (15.6) </td><td>12 (36.4) </td><td>.090\n</td></tr><tr><td>Coronary heart disease </td><td>3 (4.6) </td><td>1 (3.1) </td><td>2 (6.1) </td><td>1.000\n</td></tr><tr><td>Chronic heart failure </td><td>3 (4.6) </td><td>1 (3.1) </td><td>2 (6.1) </td><td>1.000\n</td></tr><tr><td>Cerebrovascular disease </td><td>2 (3.1) </td><td>0 </td><td>2 (6.1) </td><td>.492\n</td></tr><tr><td>Diabetes mellitus </td><td>10 (15.4) </td><td>3 (9.4) </td><td>7 (21.2) </td><td>.303\n</td></tr><tr><td>Chronic renal disease </td><td>3 (4.6) </td><td>0 </td><td>3 (9.1) </td><td>.238\n</td></tr><tr><td>Cirrhosis </td><td>1 (1.5) </td><td>1 (3.1) </td><td>0 </td><td>.492\n</td></tr><tr><td>Mental disorder b </td><td>2 (3.1) </td><td>1 (3.1) </td><td>1 (3.0) </td><td>1.000\n</td></tr><tr><td>Immune suppression c </td><td>4 (6.2) </td><td>0 </td><td>4 (12.1) </td><td>.114\n</td></tr><tr><td>Pregnancy </td><td>2 (3.1) </td><td>0 </td><td>2 (6.1) </td><td>.492\n</td></tr><tr><td>Postpartum </td><td>1 (1.5) </td><td>0 </td><td>1 (3.0) </td><td>1.000\n</td></tr><tr><td>Current smoker </td><td>19 (29.2) </td><td>6 (18.8) </td><td>13 (39.4) </td><td>.067\n</td></tr><tr><td>Symptoms and signs (on presentation)\n</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Fever d </td><td>65 (100) </td><td>32 (100) </td><td>33 (100) </td><td>\u2026\n</td></tr><tr><td>Body temperature, \u00b0C </td><td>39.5 (39.1-39.7) </td><td>39.5 (39.2-39.7) </td><td>39.5 (38.9-39.8) </td><td>.664\n</td></tr><tr><td>Cough and sputum production </td><td>56 (86.2) </td><td>27 (84.4) </td><td>29 (87.9) </td><td>.733\n</td></tr><tr><td>Blood in sputum </td><td>30 (46.2) </td><td>12 (37.5) </td><td>18 (54.5) </td><td>.168\n</td></tr><tr><td>Dyspnea </td><td>57 (87.7) </td><td>24 (75.0) </td><td>33 (100) </td><td>.002\n</td></tr><tr><td>Progressive dyspnea after resolution of fever </td><td>9 (13.8) </td><td>1 (3.1) </td><td>8 (24.2) </td><td>.027\n</td></tr><tr><td>Sore throat or rhinorrhea </td><td>36 (55.4) </td><td>19 (59.4) </td><td>17 (51.5) </td><td>.524\n</td></tr><tr><td>Myalgia </td><td>37 (56.9) </td><td>22 (68.8) </td><td>15 (45.5) </td><td>.058\n</td></tr><tr><td>Fatigue </td><td>60 (92.3) </td><td>30 (93.8) </td><td>30 (90.9) </td><td>1.000\n</td></tr><tr><td>Diarrhea </td><td>18 (27.7) </td><td>8 (25.0) </td><td>10 (30.3) </td><td>.633\n</td></tr><tr><td>Moist rales </td><td>52 (80.0) </td><td>21 (65.6) </td><td>31 (93.9) </td><td>.005\n</td></tr><tr><td>Wheezing </td><td>19 (29.2) </td><td>4 (12.5) </td><td>15 (45.5) </td><td>.006\n</td></tr><tr><td>Laboratory fi ndings (on presentation)\n</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td> Leukocyte count, mm 3 </td><td>5,000 (3,400-7,600) </td><td>5,700 (3,500-8,600) </td><td>5,000 (3,300-7,200) </td><td>.189\n</td></tr><tr><td> , 4000/mm 3 </td><td>21 (32.3) </td><td>10 (31.3) </td><td>11 (33.3) </td><td>.857\n</td></tr><tr><td>Lymphocyte count, mm 3 </td><td>750 (500-1,150) </td><td>920 (700-1,300) </td><td>560 (360-840) </td><td> , .001\n</td></tr><tr><td> , 1000/mm 3 </td><td>47 (72.3) </td><td>18 (56.3) </td><td>29 (87.9) </td><td>.006\n</td></tr><tr><td>Pa o 2 /F io 2 e </td><td>295 (242-374) </td><td>375 (321-412) </td><td>244 (211-290) </td><td> , .001\n</td></tr><tr><td>Serum albumin, f g/L </td><td>31.9 (27.0-35.2) </td><td>35.2 (31.5-38.2) </td><td>29.7 (24.0-33.0) </td><td> , .001\n</td></tr><tr><td>Creatine kinase, f U/L </td><td>180 (74-544) </td><td>155 (75-644) </td><td>221 (73-520) </td><td>.857\n</td></tr><tr><td>Lactate dehydrogenase, f U/L </td><td>345 (272-501) </td><td>290 (201-411) </td><td>404 (314-548) </td><td>.004\n</td></tr><tr><td>Alanine aminotransferase, f U/L </td><td>30 (22-44) </td><td>30 (27-53) </td><td>29 (20-42) </td><td>.164\n</td></tr><tr><td>Aspartate aminotransferase, f U/L </td><td>55 (34-99) </td><td>45 (27-86) </td><td>57 (40-106) </td><td>.245\n</td></tr><tr><td>Potassium, f mmol/L </td><td>3.8 (3.5-4.0) </td><td>3.5 (3.2-4.0) </td><td>3.8 (3.6-4.2) </td><td>.033\n</td></tr><tr><td> , 3.5 mmol/L </td><td>14 (21.5) </td><td>10 (31.3) </td><td>4 (12.1) </td><td>.028\n</td></tr><tr><td>Sodium, f mmol/L </td><td>133.5 (130.9-136.3) </td><td>133.6 (131.5-135.6) </td><td>133.4 (129.1-136.5) </td><td>.572\n</td></tr><tr><td>Procalcitonin, f ng/mL </td><td>0.29 (0.05-0.99) </td><td>0.09 (0.05-0.73) </td><td>0.46 (0.15-1.01) </td><td>.170\n</td></tr><tr><td>APACHE II score </td><td>8 (4-11) </td><td>4 (2-6) </td><td>11 (9-13) </td><td> , .001\n</td></tr><tr><td>Initial radiographic fi ndings\n</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chest radiograph g </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>No. of involved zones  3 </td><td>38/57 (66.7) </td><td>13/29 (44.8) </td><td>25/28 (89.3) </td><td>.001\n</td></tr><tr><td>Bilateral infi ltrate </td><td>41/57 (71.9) </td><td>14/29 (48.3) </td><td>27/28 (96.4) </td><td> , .001\n</td></tr><tr><td>High-resolution chest CT scan h </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>No. involved zones </td><td>6 (4-6) </td><td>4 (4-5) </td><td>6 (5-6) </td><td> , .001\n</td></tr><tr><td>Ground-glass opacities </td><td>31/35 (88.6) </td><td>11/14 (78.6) </td><td>20/21 (95.2) </td><td>.279\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(Continued)\n</td></tr></table></body></html>"}, "TABREF1": {"text": "(Continued)", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>\u00a0</td><td>Patients\n</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Variable\n</td><td>Total (N 5 65) a </td><td>Without ARDS (n 5 32)a </td><td>With ARDS (n 5 33)a </td><td> P Value </td></tr><tr><td>Consolidation </td><td>27/35 (77.1) </td><td>8/14 (57.1) </td><td>19/21 (90.5) </td><td>.039\n</td></tr><tr><td>Centrilobular nodules </td><td>15/35 (42.9) </td><td>5/14 (35.7) </td><td>10/21 (47.6) </td><td>.728\n</td></tr><tr><td>Pleural effusion </td><td>9/35 (25.7) </td><td>3/14 (21.4) </td><td>6/21 (28.6) </td><td>.712\n</td></tr><tr><td>Clinical course\n</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Days from onset of symptoms to ED </td><td>5 (4-6) </td><td>5 (4-6) </td><td>5 (4-7) </td><td>.383\n</td></tr><tr><td>Duration of fever, d </td><td>6.0 (4.0-7.0) </td><td>6.0 (4.5-6.8) </td><td>6.0 (4.0-7.3) </td><td>.665\n</td></tr><tr><td>Antiviral therapy (oseltamivir) </td><td>62 (95.4) </td><td>29 (90.6) </td><td>33 (100) </td><td>.114\n</td></tr><tr><td>150 mg bid po </td><td>23 (37.1) </td><td>6 (20.7) </td><td>17 (51.5) </td><td>.012\n</td></tr><tr><td>Duration of antiviral, d </td><td>5 (5-7) </td><td>5 (5-5) </td><td>6 (5-8) </td><td> , .001\n</td></tr><tr><td>Duration of antiviral 5 d </td><td>21 (33.9) </td><td>0 </td><td>21 (63.6) </td><td> , .001\n</td></tr><tr><td>Interval from onset to antiviral  48 h </td><td>6 (9.7) </td><td>4 (13.8) </td><td>2 (6.1) </td><td>.405\n</td></tr><tr><td>Use of antibiotics </td><td>49 (75.4) </td><td>20 (62.5) </td><td>29 (87.9) </td><td>.023\n</td></tr><tr><td>Use of corticosteroids </td><td>31 (47.7) </td><td>5 (15.6) </td><td>26 (78.8) </td><td> , .001\n</td></tr><tr><td>Mechanical ventilation </td><td>25 (38.5) </td><td>1 (3.1) </td><td>24 (72.7) </td><td> , .001\n</td></tr><tr><td>Invasive </td><td>10 (15.4) </td><td>0 </td><td>10 (30.3) </td><td>.001\n</td></tr><tr><td>Noninvasive </td><td>15 (23.1) </td><td>1 (3.1) </td><td>14 (42.4) </td><td> , .001\n</td></tr><tr><td>Extracorporeal membrane oxygenation </td><td>2 (3.1) </td><td>0 </td><td>2 (6.1) </td><td>.492\n</td></tr><tr><td>Renal replacement therapy </td><td>3 (4.6) </td><td>0 </td><td>3 (9.1) </td><td>.238\n</td></tr><tr><td>Acute liver function failure </td><td>1 (1.5) </td><td>0 </td><td>1 (3.0) </td><td>1.000\n</td></tr><tr><td>Hypotension needed vasopressor </td><td>7 (10.8) </td><td>0 </td><td>7 (21.2) </td><td>.011\n</td></tr><tr><td>Positive culture on presentation or during hospitalization\n</td><td>13 (20.0) </td><td>1 (3.1) </td><td>12 (36.4) </td><td>.001\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Bacterial </td><td>7 (10.8) </td><td>1 (3.1) </td><td>6 (18.2) </td><td>.105\n</td></tr><tr><td>Fungal </td><td>2 (3.1) </td><td>0 </td><td>2 (6.1) </td><td>.492\n</td></tr><tr><td>Bacterial and fungal </td><td>4 (6.2) </td><td>0 </td><td>4 (12.1) </td><td>.114\n</td></tr><tr><td>Length of stay in hospital for survivors </td><td>7.0 (5.3-11.0) </td><td>5.0 (4.0-6.5) </td><td>11.0 (7.0-13.0) </td><td> , .001\n</td></tr><tr><td>(n 5 41), d\n</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Death </td><td>9 (13.8) </td><td>0 </td><td>9 (27.3) </td><td>.002\n</td></tr><tr><td>Days from onset of symptoms to death </td><td>16 (10-24) </td><td>\u2026 </td><td>16 (10-24) </td><td>\u2026\n</td></tr><tr><td>Days from admission to death </td><td>9 (4-16) </td><td>\u2026 </td><td>9 (4-16) </td><td>\u2026\n</td></tr></table></body></html>"}, "TABREF2": {"text": "Analysis of HRCT Scanning During Follow-upData are presented as No. (%) of patients, unless otherwise indicated. Of the 20 patients who had \u0546 1 follow-up visits, four made all three visits, one made visits one and two, four made visits one and three, and two made visits two and three. The other 9 patients made only one visit (visit one for three of them, visit two for two of them, and visit three for four of them ). GGOs 5 ground-glass opacities; HRCT 5 high-resolution CT.", "latex": null, "type": "table"}, "TABREF3": {"text": "Analysis", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Univariate Analysis </td><td>Multivariate Analysis\n</td></tr><tr><td>Variable\n</td><td>Patients Who Survived (n 5 56)\n</td><td>Patients Who Died (n 5 9)\n</td><td>Relative Risk (95% CI) </td><td> P Value\n</td><td>Relative Risk (95% CI) </td><td> P Value\n</td></tr><tr><td>Hemoptysis, No. (%) </td><td>22 (39.3) </td><td>8 (88.9) </td><td>10.288 (1.286-82.309) </td><td>.028 </td><td>\u2026 </td><td>.217\n</td></tr><tr><td>Progressive dyspnea after resolution of fever, No. (%)\n</td><td>5 (8.9) </td><td>4 (44.4) </td><td>5.173 (1.386-19.304) </td><td>.014 </td><td>5.852 (1.395-24.541) </td><td>.016\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Lymphocyte count, mm 3 </td><td>800 (605-1,300) </td><td>330 (300-640) </td><td>0.028 (0.002-0.328) </td><td>.004 </td><td>\u2026 </td><td>.182\n</td></tr><tr><td>Pa o 2 /F io 2 a </td><td>302 (246-382) </td><td>215 (164-277) </td><td>0.990 (0.982-0.997) </td><td>.006 </td><td>\u2026 </td><td>.860\n</td></tr><tr><td>Serum albumin, b g/L </td><td>32.3 (29.9-35.6) </td><td>25.7 (20.8-27.1) </td><td>0.850 (0.774-0.933) </td><td>.001 </td><td>\u2026 </td><td>.447\n</td></tr><tr><td>Lactate dehydrogenase, b U/L </td><td>325 (246-474) </td><td>546 (454-637) </td><td>1.005 (1.002-1.008) </td><td>.001 </td><td>\u2026 </td><td>.528\n</td></tr><tr><td>Imaging fi nding involved all six zones, No. (%)\n</td><td>16 (28.6) </td><td>7 (77.8) </td><td>7.548 (1.566-36.388) </td><td>.012 </td><td>\u2026 </td><td>.389\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>APACHE II score on presentation </td><td>7 (3-10) </td><td>13 (11-14) </td><td>1.276 (1.130-1.441) </td><td> , .001 </td><td>1.312 (1.140-1.511) </td><td> , .001\n</td></tr><tr><td>Days from onset of symptoms to ED </td><td>5 (4-6) </td><td>6 (5-8) </td><td>1.319 (1.103-1.578) </td><td>.002 </td><td>\u2026 </td><td>.455\n</td></tr></table></body></html>"}, "TABREF4": {"text": "LFT Results and HRCT Scanning Patterns for 13 Discharged Patients With A(H1N1) Pneumonia, Performed at Visit Three (3 Mo After Onset of Illness)PatientNo. Sex/Age Underlying Condition ARDS/NPPV FEV 1 , % FEV 1 /FVC, % TLC, % D lco , % D lco /VA, % HRCT Scan Findings the Same Day LFTs Were Performed (Involved Zones ) obstructive sleep apnea syndrome; TLC 5 total lung capacity. See Tables 2 and 3 for expansion of other abbreviations.HRCT scan of this 56-y-old woman also presented diffuse pleural thickening and calcifi cation, which indicated the pleural disease she had in the past, but she could not remember the details.", "latex": null, "type": "table"}}, "back_matter": [{"text": "Author contributions: Dr Bai: contributed to data collection and analysis and the fi rst draft of the manuscript. Dr Gu: contributed to data collection and analysis. Dr Cao: contributed to data collection and analysis, the fi rst draft of the manuscript, and revision of the manuscript . Dr Zhai: contributed to radiologic evaluation and review and revision of the manuscript. Dr M. Lu : contributed to postmortem examination and review and revision of the manuscript. Dr Y. Lu: contributed to lung function testing and review and revision of the manuscript. Dr Liang: contributed to statistical analysis and review and revision of the manuscript. Dr Zhang: contributed to radiologic evaluation and review and revision of the manuscript. Dr Gao: contributed to postmortem examination and review and revision of the manuscript. Dr Huang: contributed to lung function testing and review and revision of the manuscript. Dr Liu: contributed to infl uenza virus testing and review and revision of the manuscript. Dr Song: contributed to data collection and review and revision of the manuscript. Dr Wu: contributed to data collection and review and revision of the manuscript. Dr Yin: contributed to data collection and review and revision of the manuscript. Dr Wang: contributed to data analysis and careful revision of the manuscript. Financial/nonfi nancial disclosures: The authors have reported to CHEST that no potential confl icts of interest exist with any companies/organizations whose products or services may be discussed in this article . Other contributions: All work was performed at the Beijing Chao-Yang Hospital, Capital Medical University and the School of Basic Medical Sciences, Peking University, Bejing, China. We", "cite_spans": [], "ref_spans": [], "section": "annex"}]}